GlaxoSmithKline (GSK) Earnings Dates, Call Summary & Reports

Q: What is the P/E ratio of GlaxoSmithKline stock?

The P/E ratio of {name} is N/A.

Compare

1,144 Followers

Earnings Data

Report Date

Apr 29, 2026

Before Open (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

0.43

Last Year’s EPS

0.45

Same Quarter Last Year

Analyst Consensus

Hold

Based on 12 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Feb 04, 2026|

% Change Since:

Earnings Call Sentiment|Positive

Overall the call conveys a predominantly positive outlook: the company reported solid 2025 financial performance (sales +7%, core op profit +11%, EPS +12%), strong cash generation, continued pipeline momentum (5 FDA approvals, 7 new pivotal trials, multiple Phase III starts planned), and affirmative 2026 guidance (sales +3%–5%, core profit/EPS +7%–9%). Key growth drivers are specialty medicines (up 17%), oncology, HIV long-acting injectables, and vaccines ex‑U.S. Notable challenges include product-specific declines (e.g., ZEJULA), launch cadence and coordination issues for BLENREP and Exdensur, one-off Q4 charges (£300m), Zantac-related cash outflows (£1.9bn total), currency exposure (potential −3% sales/−6% op profit), and ongoing pricing/generic pressures in GenMed. On balance, the breadth of positive financial metrics, strong cash flow, clear pipeline milestones and constructive guidance outweigh the flagged headwinds.

Company Guidance

GSK guided 2026 to "another year of top-line growth" with sales growth of 3–5% at constant exchange rates, core operating profit and core EPS each expected to grow 7–9%, and a dividend raised to 70p (a 6% increase); product-area guidance sees specialty growing low double-digits (HIV mid‑ to high‑single digits) while vaccines and General Medicines are expected to be low single‑digit decline to stable, with sales evenly phased through the year. On the P&L, gross margin should continue to benefit from supply‑chain efficiencies and the shift to specialty, SG&A is expected to grow low single‑digit, R&D to grow ahead of sales, interest and tax charges to increase (partly offsetting EPS via the share buyback), and operating‑profit phasing is skewed to H2 reflecting GBP300m of Q4’25 productivity charges and the Q2 annualisation of the RSV settlement. Management warned of currency headwinds at Jan‑28 closing rates (≈‑3% on sales and ≈‑6% on operating profit), reiterated that mid‑point guidance implies an 8% sales CAGR and 13% operating‑profit CAGR for 2021–26, and said cash generation is on track for >GBP10bn in 2026 (CFO GBP8.9bn or >GBP10bn ex‑Zantac; FCF GBP4bn or >GBP5bn ex‑Zantac), with net debt/EBITDA around 1.3x and remaining shareholder buyback of GBP0.6bn to complete in H1.

Strong Top-Line Growth

Full-year sales up 7% to >£32 billion (FY2025). 2026 headline guidance: sales growth 3%–5% at constant exchange rates.

Specialty Medicines Momentum

Specialty medicines sales up 17% in 2025; company expects specialty to deliver low double-digit growth in 2026.

Profitability and EPS Expansion

Core operating profit grew 11% and core EPS rose 12% in 2025. Guidance for 2026 calls for core operating profit and core EPS growth of 7%–9%.

Strong Cash Generation and Balance Sheet

Cash generated from operations £8.9bn in 2025 (and >£10bn excluding Zantac); free cash flow £4.0bn (or >£5.0bn excluding Zantac). Net debt/EBITDA stable at ~1.3x.

Shareholder Returns Increased

Dividend upgraded by 2p to 66p declared for FY2025; guidance includes a 70p dividend for 2026 (6% increase). Share buyback: 93 million shares repurchased (avg price 1473) with ~£0.6bn remaining.

R&D Output and Pipeline Progress

Five FDA approvals and seven new pivotal trial starts in 2025. Ten pivotal starts planned for 2026 (including >5 ADC starts, 2 advanced MASH, and QUATRO Q4M HIV trial).

Notable Product & Category Growth

Respiratory Immunology and Inflammation up 18%; Benlysta +22%; Nucala +15 (Nucala delivered $2bn in 2025 and achieved 10th consecutive year of double-digit growth). Oncology sales up 43% with Jemperli +89% and Ojjaara +60%.

HIV Franchise Momentum

HIV sales +11% in 2025. Cabenuva grew 42% and now accounts for >75% market share in the U.S. this quarter; long-acting injectables drove >75% of HIV growth and represent ~1/3 of U.S. sales. 2026 HIV guidance: mid- to high-single-digit growth.

Vaccines Performance

Vaccines sales £9.2bn (+2%); Shingrix £3.6bn (+8%); Bexsero up 16% driven by Europe and international programs. 2026 expectation: Shingrix performance supported ex-U.S. and ex-China; vaccines overall low single-digit decline to stable.

Margin and Operational Leverage

Operating margin increased by 110 basis points in 2025 (reported margin 29.9% impacted by currency). Over four years, core margin accretion of ~470 basis points at CER. SG&A improvement and portfolio shift to specialty contributed to margin expansion.

Successful Business Development

Acquisition agreement announced to acquire Rapp Therapeutics (Ozureprubart for food allergy). Continued BD to add high-value clinical-stage specialty assets and platform deals; £4.5bn deployed in CapEx and BD in 2025.

Key Positive Clinical Readouts & Milestones

Positive B-WELL 1 & 2 Phase III results for bepirovirsen in chronic hepatitis B; KALM-2 last patient first visit achieved; Efimosfermin Phase III started; Velzatinib Phase III initiated for 2nd-line GIST. Multiple pivotal readouts and registrational starts scheduled for 2026–2028.

GlaxoSmithKline (GB:GSK) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GB:GSK Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Apr 29, 2026	2026 (Q1)	0.43 / -	0.449	―	―	―
Feb 04, 2026	2025 (Q4)	0.24 / 0.26	0.232	9.91% (+0.02)	―	―
Oct 29, 2025	2025 (Q3)	0.47 / 0.55	0.497	10.66% (+0.05)	―	―
Apr 30, 2025	2025 (Q1)	0.40 / 0.45	0.431	4.18% (+0.02)	―	―
Feb 05, 2025	2024 (Q4)	0.20 / 0.23	0.289	-19.72% (-0.06)	―	―
Oct 30, 2024	2024 (Q3)	0.44 / 0.50	0.504	-1.39% (>-0.01)	―	―
Jul 31, 2024	2024 (Q2)	0.38 / 0.43	0.388	11.86% (+0.05)	―	―
May 01, 2024	2024 (Q1)	0.37 / 0.43	0.37	16.49% (+0.06)	―	―
Jan 31, 2024	2023 (Q4)	0.29 / 0.29	0.258	12.02% (+0.03)	―	―
Nov 01, 2023	2023 (Q3)	0.46 / 0.50	0.469	7.46% (+0.04)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GB:GSK Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 04, 2026	1930.06 p	2063.49 p	+6.91%
Oct 29, 2025	1616.64 p	1722.84 p	+6.57%
Apr 30, 2025	1376.09 p	1425.58 p	+3.60%
Feb 05, 2025	1311.36 p	1411.13 p	+7.61%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does GlaxoSmithKline (GB:GSK) report earnings?

GlaxoSmithKline (GB:GSK) is schdueled to report earning on Apr 29, 2026, Before Open (Confirmed).

What is GlaxoSmithKline (GB:GSK) earnings time?

GlaxoSmithKline (GB:GSK) earnings time is at Apr 29, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of GlaxoSmithKline stock?

The P/E ratio of GlaxoSmithKline is N/A.

What is GB:GSK EPS forecast?

GB:GSK EPS forecast for the fiscal quarter 2026 (Q1) is 0.43.